Publicaciones en las que colabora con Alfonso Berrocal Jaime (10)

2024

  1. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

    The Lancet Oncology

2020

  1. A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)

    Neuro-oncology, Vol. 22, Núm. 12, pp. 1851-1861

2019

  1. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

    The Lancet, Vol. 393, Núm. 10167, pp. 156-167

2018

  1. Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients

    Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1529-1537

2016

  1. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial

    Journal of Neuro-Oncology, Vol. 127, Núm. 3, pp. 569-579

2015

  1. A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma

    Clinical and Translational Oncology, Vol. 17, Núm. 9, pp. 743-750

2014

  1. Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry

    Journal of Neuro-Oncology, Vol. 116, Núm. 2, pp. 413-419

  2. Erratum: Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry [J Neurooncol, 116, (2014), 413-419, DOI 10.1007/s11060-013-1316-y]

    Journal of Neuro-Oncology

2012

  1. SEOM guideline for the treatment of malignant glioma

    Clinical and Translational Oncology, Vol. 14, Núm. 7, pp. 545-550

2010

  1. Extended-schedule dose-dense temozolomide in refractory gliomas

    Journal of Neuro-Oncology, Vol. 96, Núm. 3, pp. 417-422